Abstract
INTRODUCTION
There is widespread evidence that only 30-50% of patients are adherent to the medicines prescribed for long-term physical or mental health problems (1) . This leads to reduced clinical benefit, avoidable morbidity and mortality and medication wastage. Measuring adherence presents a challenge to researchers as there are only a few conditions, such as gout where biomarkers can provide a direct assessment of the amount of medicine taken. While there are electronic monitoring measures which can be incorporated medicines containers, these are quite costly and so researchers often rely on self-report measures, such as the Medication Adherence Report Scale (2) , which was used in the present study (see below).
Numerous interventions have been developed for facilitating medicines adherence (3,4) but sub-optimal adherence continues to be a massive problem in healthcare (1, 5) . Although research has shown that there are multiple factors underlying poor adherence (6, 7) , interventions still often rely on fairly simple unidimensional solutions, such as reminders (8) , which have shown limited efficacy at best. While early research focused more on unintentional factors, such as forgetting (9) , more recent studies have highlighted the importance of intentional factors, arising from patients' beliefs and levels of motivation and engagement . Many studies therefore incorporate measures, such as the Beliefs about Medicines Questionnaire (10) and the Patient Activation Measure (11) to capture these additional variables ( see methods section).
While the number of recognised determinants of adherence has grown, evidence from systematic reviews (5, 12) indicates there is still considerable unexplained variance. Even within the domain of intentional non-adherence, there is still an
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emphasis on the negative aspects of treatment, such as side effects, which may cause patients to have concerns about taking their prescribed medicine. Thus, the aim of the present study was to develop and test a new measure, which could assess different components of intentional non-adherence and to determine whether these could explain additional variance in behavioural and biomarker measures of non-adherence.
Rather than relying on existing theoretical constructs, such as risk perceptions or beliefs about the pros and cons of medicines, we attempted to identify intentional factors that get in the way of adhering to medical treatment from the patient's own perspective. We were able to do this from two distinct sources. First, from our previous studies, where we had data from interviews or free text responses, we could identify various reasons, which patients provided for not taking their medicines.
These included factors relating to people's illness beliefs, their perceptions of their own identity and the way in which medicine could have a negative impact on this (e.g., medicine is an unwanted reminder of being unwell).
The second source of possible factors came from the qualitative research literature, which has revealed a range of reasons from in-depth interviews exploring patients' views about their prescribed medicines (13, 14) . An overview by Pound and colleagues (14) conceptualised non-adherence as a preference to minimize the intake of medicines and describe this as "resisting medicines" since the medicines can often be perceived as an unwanted reminder of illness and hence as a threat to self-identity. We therefore selected items to reflect this broader range of reasons for intentional non-adherence to ascertain their potential explanatory role in medication adherence, and to see if they could be grouped into any broader scales. We also
sought to compare the explanatory power of this new measure with some widely used predictors of adherence.
METHODS

Item selection
Two of the authors (KP;JW) examined their own datasets as well as results from qualitative research on treatment adherence to select items which did not seem to be present in existing adherence prediction measures , such as the Beliefs about Medicine Questionnaire (BMQ) (10) and the Patient Activation Measure (PAM) (11) .
After generating a long list of over 30 items, we examined this for duplicates or ambiguous items and ended up with a shortlist of 22 items, which are shown in Appendix 1.
Patient samples
Patients from 3 different outpatient clinics provided data for this study, as follows:
(i) 175 patients attending routine hypertension outpatient clinics at two large London teaching hospitals. Of these 74 (mean age = 56.2 years; 44 female, 30 male) were used for the main psychometric analyses and 101
(mean age 51.5 years; 62 F,39M) were from a separate study comparing the new measure and PAM scales (see below).
(ii) 115 patients (mean age 62.2 years; 41 female, 68 male) attending an
Oncology outpatient clinic at a large London teaching hospital and for whom medication was now their primary treatment.
(iii) 196 patients (mean age = 61.6 years; 28 female, 168 male) with gout and being treated with an urate lowering medication were recruited from a A C C E P T E D M A N U S C R I P T 
Measures
Intentional non-adherence
The Intentional Non-Adherence Scale (INAS) is a 22-item scale identifying varying reasons why patients may intentionally stop taking their medications as prescribed. 
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Medication adherence
In the hypertension and oncology samples, adherence to medication was assessed using the Medication Adherence Report Scale (MARS-5) (2), a validated 5-item self-report scale. The MARS-5 consists of 5 common patterns of non-adherent
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A C C E P T E D M A N U S C R I P T give a cumulative score ranging from 5 to 25, with higher scores indicating higher levels of reported adherence.
With the Gout sample, adherence to medication was assessed by a biomarker from a patient's serum urate (SU) level (details in section on patient samples above).
Since the aim of treatment is to lower the elevated SU levels, patient adherence can be directly assessed from their (SU) level as an objective physiological marker, which is a gold standard measure of adherence to urate lowering medication.
Beliefs about Medicines
In the hypertension and oncology samples, the Beliefs about Medicines Questionnaires-Specific (BMQ-Specific) (10) was used. This is a widely used, where the researcher identified and approached eligible participants in the waiting room, inviting them to take part in the study and complete a questionnaire either before or after their consultation appointment. If patients were willing to take part in the study, an introduction to the study was provided by the researcher, which described the purpose of the research, the nature of their involvement and how this would contribute to the research study. The researcher was in attendance throughout administration, providing information and support or discussing any concerns, if needed. The clinician lead was also available throughout, should the participant need to receive any additional support and resources.
Of the 158 oncology patients on the clinic schedule that were eligible for inclusion, 32 refused to take part in the study, 3 individuals initially agreed to take part, but later withdrew without competing the questionnaire due to time constraints. Eight individuals asked to complete the questionnaire via the free-post self-addressed
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postal system but none of these were returned. Overall, 115 patients completed and returned the questionnaire, giving an overall response rate of 115/158 (72.7%) .
Within the hypertension clinics of the 82 study-eligible patients that were approached, 3 declined to take part and 5 requested to complete the questionnaire off-site via the free-post postal system but none of these were returned. The final study sample resulted in a completion response rate of 74/82 (90.2%).
With the gout sample, 277 patients were approached and 196 agreed to participate, resulting in a response rate of 70.8 %
Statistical analysis
A maximum likelihood Exploratory Factor Analysis (EFA) with an oblique rotation (Promax) was conducted in STATA. Prior to performing the EFA, suitability of the item pool for factor analysis was assessed using Kaiser-Meyer-Olkin's test. Factor retention criterion was determined by the Kaiser criterion (eigenvalues >1), scree plot and parallel analysis (18) . Items were removed from the EFA if their factor loadings were non-significant or if they loaded significantly but weakly (i.e., <.40) onto more than one factor. The resultant factor scales were labelled in accordance with the data output. Differences between means of INAS subscales across patient diagnoses (oncology, hypertension and gout) were assessed using ANOVA.
Further Pearson's correlation analyses were conducted using data from the Gout sample to examine associations between the subscales of the INAS, the BIPQ and a biomarker measure of adherence (serum urate levels). An independent samples ttest was performed to compare patients who reached or exceeded the serum target level of 0.36 mm/L with those whose serum levels were below the target. In a subsample of 30 gout patients, the intraclass correlation coefficient (ICC) was used to assess test-retest reliability of the new measure over a 4 week period.
RESULTS
(a) Preliminary analysis
Means and standard deviations for each of the INAS items are shown in appendix 1.
Only participants with complete data for INAS (98.8%) were included in the analysis.
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Histograms and Q-Q plots showed that four items were highly skewed and thus were excluded. The inter-item correlations for the remaining 18 cases were examined. All items correlated positively and significantly (p>.001) with each other. Kaiser-MeyerOlkin's test was performed to assess the suitability of the item pool for factor analysis. Considering all 18 items together, the overall Kaiser-Meyer-Olkin was .94, exceeding the recommended minimum value of .60 (18) for conducting an EFA.
(b) Exploratory Factor Analysis (EFA)
A maximum likelihood EFA of the 18-items assessing intentional non-adherence to prescribed treatments revealed the presence of two factors with an eigenvalue exceeding 1, which together explained 91% of the total variance (factor 1, 83%; factor 2, 8%). Although factor 2 only explained a small proportion of total variance, the scree-plot, parallel analysis and eigenvalue rule all suggested that two factors should be extracted. The factor matrix showed that 8 items loaded on the first factor (all >0.6) and 5 items loaded on the second factor (all >0.6). Five items loaded significantly on both factors, and thus were discarded. Re-factoring on the remaining 13 items produced a similar two factor structure explaining 93% of the variance. The correlation between the two factors was .65.
The final 2-factor structure of the 13-item scale is shown in Table 1 . The first factor comprised 8 items linking the decision not to take treatment with not wanting to be reminded of one's illness, the association of medication with illness and the desire to feel 'normal'. This factor was labelled "Resisting Illness"(RI). The second factor has been labelled "Testing Treatment (TT)" as it comprised 5 items assessing reasons for not taking treatment based on the person's attempts to see if they can get away with taking less or no treatment.
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The two INAS sub-scales achieved high levels of internal consistency. For the 8-items forming the Resisting Illness (RI) scale, the Cronbach alpha co-efficient was .95 , and for the 5-items forming the Testing treatment (TT) scale the alpha was .93.
In the 30 participants with gout who were re-assessed after a 4-week period, testretest reliability for the Testing treatment scale showed an intraclass correlation (ICC) of .97 and for the Resisting illness scale the ICC was .95.
(d) Validity
The validity of the 2 INAS subscales was evaluated in a number of ways. First, we
wanted to see whether they correlated with both self-reported and biomarker measures of treatment adherence. Second, we wanted to examine possible associations with a range of measures, which have been found to explain adherence and self-management behaviours, and to compare the explanatory power of the INAS scales with these measures. Finally, we wanted to determine the extent to which the INAS scores discriminated between the three different clinical groups from whom we collected data.
Adherence
Self-reported adherence
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Correlations between the two INAS subscales and the MARS are shown in Table 2 .
In the combined hypertension and oncology sample, both INAS subscales significantly and negatively correlated with self-reported adherence to medicine. Very similar patterns of correlation were found for these two patient groups but these effects were slightly stronger in the Oncology sample (r=-.57 and .-61, TT and RI respectively) compared with the Hypertension sample (r=-.53 and -43, TT and RI respectively).
Biomarker measure of adherence
In the Gout sample, moderate but significant positive correlations were found between serum urate levels and both the Testing Treatment (r=.42) and Resisting Illness (r=.48) subscales of the INAS (see Table 2 ). An independent-sample t-test 
Beliefs about medicines, illness perceptions and patient activation.
In the hypertension and oncology samples, patients completed the BMQ together with the INAS and the MARS. We did this to examine the extent to which the INAS subscales overlapped with the Necessity and Concerns scales of the BMQ. The results showed a very similar pattern of correlations for the group as a whole and for
A C C E P T E D M A N U S C R I P T
both patient groups (see Table 2 ). Both INAS scales correlated moderately with the BMQ Concerns scale, emphasising that the INAS items were tapping into various worries that patients had about their medicines but that there was still considerable unexplained variance. In contrast, no correlations were found with the BMQ Necessity scale. In order to compare the variance in adherence self-report explained by the INAS and BMQ, we conducted a multiple regression analysis. The results reported in Table 3 show that while BMQ Concerns was significantly associated with Concerns (see Table 2 ).
We also wanted to ensure that the INAS scales were sufficiently distinct from various self-regulatory constructs, such as personal control and patient activation. In the gout sample, it can be seen that there are no significant correlations with BIPQ Personal Control (Table 2) . Similarly, in a sample of 101 hypertensive patients, no correlations were found with the PAM. In this sample we also conducted a multiple linear regression to evaluate whether patient activation, medication beliefs and reasons for intentional non-adherence predicted medication adherence while controlling for age 
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A C C E P T E D M A N U S C R I P T Highlights  The INAS contains two new scales assessing reasons for non-adherence to treatment.  Patients may not adhere because they do not want to be reminded of their illness  Others attempt to see if they can get away with taking less or no treatment.  Both factors explain unique variance in subjective and objective adherence markers
